Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Investing.com - Raymond James downgraded Tvardi Therapeutics Inc (NASDAQ:TVRD) from Outperform to Market Perform following unsuccessful results from the company’s REVERT-IPF clinical trial. The stock has plummeted over 83% in the past week, currently trading at $6.69, significantly below its 52-week high of $43.65.
The downgrade comes after the trial for TTI-101 raised significant concerns, particularly regarding gastrointestinal adverse events that led to high discontinuation rates in treatment arms and an unexpectedly low placebo FVC response rate. According to InvestingPro data, four analysts have recently revised their earnings downwards for the upcoming period.
Tvardi plans to shift focus to its Phase 2 REVERT-Liver Cancer study, which is expected to report topline results in the first half of 2026, with current cash reserves projected to support operations into the fourth quarter of 2026. The company maintains a strong liquidity position with a current ratio of 4.04, and notably holds more cash than debt on its balance sheet.
Raymond James noted that while initial tumor response results from this study and a prior Phase 1 basket study in solid tumors show promise, the high discontinuation rate observed in the IPF trial adds risk to Tvardi’s development program.
The firm removed the IPF opportunity from its financial model for Tvardi, citing the aggregate of these factors as the basis for its downgrade decision.
In other recent news, Tvardi Therapeutics has faced significant challenges following the release of preliminary results from its Phase 2 REVERT-IPF trial. The trial, which evaluated the effectiveness of Tvardi’s lead STAT3 inhibitor, TTI-101, in treating idiopathic pulmonary fibrosis (IPF), did not meet its goals. This outcome has led to a series of analyst actions affecting the company’s outlook. BTIG has lowered its price target for Tvardi to $15, down from $55, while maintaining a Buy rating. Similarly, Oppenheimer has significantly reduced its price target to $10 from $65, though it continues to rate the stock as Outperform. Despite these setbacks, Barclays has initiated coverage of Tvardi with an Overweight rating and set a price target of $61. The trial involved 88 patients and examined TTI-101 both as a standalone treatment and in combination with nintedanib. These developments underscore the challenges Tvardi faces in advancing its treatment for IPF.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.